-+ 0.00%
-+ 0.00%
-+ 0.00%

Modus Therapeutics says sevuparin trial in children with severe malaria is published in Nature Communications

PUBT·10/21/2026 09:34:03
Listen to the news
Modus Therapeutics says sevuparin trial in children with severe malaria is published in Nature Communications
  • Modus Therapeutics’ Phase Ib SEVUSMART results for sevuparin in children with severe malaria were published today in Nature Communications.
  • The 23-child study identified a dose for further testing, with no clinical bleeding complications despite modest changes in a coagulation marker.
  • Mortality was below expectations, but the uncontrolled study requires confirmation in a controlled trial.
  • Next steps include planning a Phase II study; Modus holds commercial rights to sevuparin.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modus Therapeutics Holding AB published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.